Rosita Curcio1, Donatella Aiello2, Angelo Vozza3, Luigina Muto1, Emanuela Martello1, Anna Rita Cappello1, Loredana Capobianco4, Giuseppe Fiermonte3, Carlo Siciliano1, Anna Napoli5, Vincenza Dolce6. 1. Department of Pharmacy, Health, and Nutritional Sciences, University of Calabria, 87036, Arcavacata di Rende, Cosenza, Italy. 2. Department of Chemistry and Chemical Technologies, University of Calabria, 87036, Arcavacata di Rende, Cosenza, Italy. 3. Laboratory of Biochemistry and Molecular Biology, Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, 70125, Bari, Italy. 4. Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100, Lecce, Italy. 5. Department of Chemistry and Chemical Technologies, University of Calabria, 87036, Arcavacata di Rende, Cosenza, Italy. amc.napoli@unical.it. 6. Department of Pharmacy, Health, and Nutritional Sciences, University of Calabria, 87036, Arcavacata di Rende, Cosenza, Italy. vincenza.dolce@unical.it.
Abstract
3-hydroxy-3-methyl glutaryl-CoA reductase, also known as HMGR, plays a crucial role in regulating cholesterol biosynthesis and represents the main pharmacological target of statins. In mammals, this enzyme localizes to the endoplasmic reticulum membrane. HMGR includes different regions, an integral N-terminal domain connected by a linker-region to a cytosolic C-terminal domain, the latter being responsible for enzymatic activity. The aim of this work was to design a simple strategy for cloning, expression, and purification of the catalytic C-terminal domain of the human HMGR (cf-HMGR), in order to spectrophotometrically test its enzymatic activity. The recombinant cf-HMGR protein was heterologously expressed in Escherichia coli, purified by Ni+-agarose affinity chromatography and reconstituted in its active form. MALDI mass spectrometry was adopted to monitor purification procedure as a technique orthogonal to the classical Western blot analysis. Protein identity was validated by MS and MS/MS analysis, confirming about 82% of the recombinant sequence. The specific activity of the purified and dialyzed cf-HMGR preparation was enriched about 85-fold with respect to the supernatant obtained from cell lysate. The effective, cheap, and easy method here described could be useful for screening statin-like molecules, so simplifying the search for new drugs with hypocholesterolemic effects.
3-hydroxy-3-methyl glutaryl-CoA reductase, also known as HMGR, plays a crucial role in regulating n class="Chemical">cholesterol biosynthesis and represents the main pharmacological target of statins. In mammals, this enzyme localizes to the endoplasmic reticulum membrane. HMGR includes different regions, an integral N-terminal domain connected by a linker-region to a cytosolic C-terminal domain, the latter being responsible for enzymatic activity. The aim of this work was to design a simple strategy for cloning, expression, and purification of the catalytic C-terminal domain of the human HMGR (cf-HMGR), in order to spectrophotometrically test its enzymatic activity. The recombinant cf-HMGR protein was heterologously expressed in Escherichia coli, purified by Ni+-agarose affinity chromatography and reconstituted in its active form. MALDI mass spectrometry was adopted to monitor purification procedure as a technique orthogonal to the classical Western blot analysis. Protein identity was validated by MS and MS/MS analysis, confirming about 82% of the recombinant sequence. The specific activity of the purified and dialyzed cf-HMGR preparation was enriched about 85-fold with respect to the supernatant obtained from cell lysate. The effective, cheap, and easy method here described could be useful for screening statin-like molecules, so simplifying the search for new drugs with hypocholesterolemic effects.
Entities:
Keywords:
Affinity chromatography; Bacterial expression; Enzymatic activity; HMGR; MALDI MS and MS/MS; Screening of statin-like molecules
Authors: A R Cappello; V Dolce; D Iacopetta; M Martello; M Fiorillo; R Curcio; L Muto; D Dhanyalayam Journal: Mini Rev Med Chem Date: 2016 Impact factor: 3.862
Authors: F McTaggart; L Buckett; R Davidson; G Holdgate; A McCormick; D Schneck; G Smith; M Warwick Journal: Am J Cardiol Date: 2001-03-08 Impact factor: 2.778
Authors: Donatella Aiello; Stefano Materazzi; Roberta Risoluti; Hariprasad Thangavel; Leonardo Di Donna; Fabio Mazzotti; Francesca Casadonte; Carlo Siciliano; Giovanni Sindona; Anna Napoli Journal: Mol Biosyst Date: 2015-08
Authors: Roberta Seccia; Silvia De Santis; Maria A Di Noia; Ferdinando Palmieri; Daniela V Miniero; Raffaele Marmo; Eleonora Paradies; Antonella Santoro; Ciro L Pierri; Luigi Palmieri; Carlo M T Marobbio; Angelo Vozza Journal: J Fungi (Basel) Date: 2022-07-29